TORONTO, April 20, 2018 /CNW/ - HLS Therapeutics Inc.
("HLS" or the "Company") (TSX-V: HLS), an emerging specialty
pharmaceutical company, announces that Greg
Gubitz, CEO, will present at the Bloom Burton & Co.
Healthcare Investor Conference, which takes place May 2 - May 3, 2018 at the Sheraton Centre Hotel
in downtown Toronto. HLS will
present on Wednesday May 2, 2018, at
1:30 p.m. Eastern Time, and will host
investor meetings throughout the course of the conference.
About the Conference
The Bloom Burton & Co.
Healthcare Investor Conference brings together U.S., Canadian and
international investors who are interested in the latest
developments in the Canadian healthcare sector. Attendees will have
an opportunity to obtain corporate updates from the premier
Canadian publicly traded and private companies through
presentations and private meetings.
About HLS Therapeutics Inc.
Formed in 2015, HLS is a
specialty pharmaceutical company focused on the acquisition and
commercialization of late stage development, commercial stage
promoted and established stage managed branded pharmaceutical
products in the North American markets. HLS's focus is on products
targeting the central nervous system and cardiovascular therapeutic
areas. HLS's management team is composed of seasoned pharmaceutical
executives with a strong track record of success in these
therapeutic areas and at managing products in each of these
lifecycle stages.
Forward-Looking Information
This release
includes forward-looking statements regarding HLS and its business.
Such statements are based on the current expectations and views of
future events of HLS's management. In some cases the
forward-looking statements can be identified by words or phrases
such as "may", "will", "expect", "plan", "anticipate", "intend",
"potential", "estimate", "believe" or the negative of these terms,
or other similar expressions intended to identify forward-looking
statements, including, among others, statements with respect to
HLS's pursuit of additional product and pipeline opportunities in
certain therapeutic markets, statements regarding growth
opportunities and expectations regarding financial performance. The
forward-looking events and circumstances discussed in this release
may not occur and could differ materially as a result of known and
unknown risk factors and uncertainties affecting HLS, including
risks relating to the specialty pharmaceutical industry, risks
related to the regulatory approval process, economic factors and
many other factors beyond the control of HLS. Forward-looking
statements and information by their nature are based on assumptions
and involve known and unknown risks, uncertainties and other
factors which may cause HLS's actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance or achievements expressed or
implied by such forward-looking statement or information.
Accordingly, readers should not place undue reliance on any
forward-looking statements or information. A discussion of the
material risks and assumptions associated with this release can be
found in the joint information circular of HLS and AMD dated
February 5, 2018 in respect of the
Arrangement, which has been filed on SEDAR and can be accessed at
www.sedar.com. Accordingly, readers should not place undue reliance
on any forward-looking statements or information. Except as
required by applicable securities laws, forward-looking statements
speak only as of the date on which they are made and HLS undertakes
no obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events,
or otherwise.
SOURCE HLS Therapeutics Inc.